Clinical Research Directory

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Sponsor: Alexion Pharmaceuticals, Inc.

Summary

The primary objective of this study is to evaluate the efficacy of ravulizumab in adult participants with PNH.

Official title: A Phase 3, Single-arm, Open-label, Multicenter Study to Assess the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Complement Inhibitor Treatment Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China

Key Details

Conditions

Interventions

Locations (8)